ACE Report Cover
The PARITY Trial
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
TUMOUR
The PARITY Trial .

A Trial Comparing Prophylactic Intravenous Antibiotic Regimens Following Endoprosthetic Reconstruction for Lower Extremity Bone Tumors

JAMA Oncol . 2022 Jan 6;e216628.
Contributing Authors

Investigators The PARITY

Six hundred and eleven patients undergoing surgical resection and endoprosthetic reconstruction for lower extremity bone tumors were randomized to receive a one-day regimen (n=312) or five-day regimen (n=299) of post-operative prophylactic intravenous antibiotics. The primary outcome was surgical site infection as classified according to the criteria established by the Centers for Disease Control and Prevention (CDC), within one year of surgery. Secondary outcomes of interest included antibiotic-related complications, unplanned re-operations, oncologic and functional outcomes, and mortality. There was no significant difference in surgical site infections between the two intravenous antibiotic regimens. However, the five-day regimen group had significantly more antibiotic related complications compared to the one-day regimen group. No differences in other secondary outcomes were found.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. The PARITY Trial . ACE Report. 2022;110(1):1. Available from: https://myorthoevidence.com/AceReport/Show/the-parity-trial

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report